Véronique Lecault

Véronique Lecault is the co-founder and COO of AbCellera, a multidisciplinary antibody discovery platform that searches, decodes, and analyzes natural immune systems to find antibodies for development into drugs for disease prevention and treatment. She helped to grow the business from it’s early family-funded seed round in 2012 to a US$555 public offering on the Nasdaq. AbCellera helps accelerate the drug development process, and was used to develop the first COVID-19 antibody therapy specific to SARS-CoV-2 to receive Emergency Use Authorization by the FDA. Today AbCellera has grown to over 200 employees and has received three Fast Company awards in 2020, including Innovative Team of the Year.